FDA Brief

Warning letters Drugs

FDA warning letter to

AQ USA Inc., d.b.a Ross Healthcare Inc.

High riskIssued Feb 12Posted Feb 24Center for Drug Evaluation and Research (CDER)

FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.

What happened

FDA inspected AQ USA Inc., d.b.a. Ross Healthcare Inc.’s drug manufacturing facility in Lynden, WA, from July 30 to August 12, 2025, and reviewed the company’s August 21, 2025, response to FDA’s inspection observations (Form FDA 483). FDA found that the firm released finished drug batches without adequate microbial testing, used an inappropriate component, did not test incoming raw materials for identity, lacked adequate stability data, and lacked effective quality unit oversight.

What FDA found

  1. Failed to test each finished drug batch for objectionable microorganisms and set microbial limits far above the cited standard.

    21 CFR 211.165(b) & 21 CFR 211.160(b)
  2. Failed to establish and follow adequate written procedures for receiving, testing, and approving components, containers, and closures, and used a component that did not meet the required pharmacopeial specification.

    21 CFR 211.80(a)
  3. Failed to perform at least one identity test on each incoming component and to validate suppliers’ test results (certificates of analysis) at appropriate intervals.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  4. Failed to have an adequate stability program and data to show drug products meet microbial specifications throughout their labeled shelf lives.

    21 CFR 211.166(a)
  5. The quality unit lacked adequate oversight to ensure production procedures, batch records, test method validation, and overall CGMP compliance.

    21 CFR 211.22; 21 CFR 211.100(a); 21 CFR 211.188(b); 21 CFR 211.165(e)

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrections, prevention steps, detailed testing and risk assessments, independent assessments, and remediation timelines; FDA also recommends a qualified CGMP consultant. If corrective actions cannot be completed in that time, the company must state why and give a completion schedule.

Who should pay attention

  • companies that buy or distribute AQ USA/Ross Healthcare drug products
  • brands relying on supplier certificates of analysis for raw materials
  • quality teams at nonsterile drug manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk